Literature DB >> 23643603

Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance.

Jeffrey J Tosoian1, Eric JohnBull, Bruce J Trock, Patricia Landis, Jonathan I Epstein, Alan W Partin, Patrick C Walsh, H Ballentine Carter.   

Abstract

PURPOSE: We assessed oncologic outcomes at surgery in men with low risk and very low risk prostate cancer who were candidates for active surveillance.
MATERIALS AND METHODS: In a prospectively collected institutional database, we identified 7,486 subjects eligible for active surveillance who underwent radical retropubic prostatectomy. Candidates were designated as being at low risk (stage T1c/T2a, prostate specific antigen 10 ng/ml or less, and Gleason score 6 or less) or very low risk (stage T1c, prostate specific antigen density 0.15 or less, Gleason score 6 or less, 2 or fewer positive biopsy cores, 50% or less cancer involvement per core) based on preoperative data. Adverse findings were Gleason score upgrade (score 7 or greater) and nonorgan confined cancer on surgical pathology. The relative risk of adverse findings in men at low risk with very low risk disease was evaluated in a multivariate model using Poisson regression.
RESULTS: A total of 7,333 subjects met the criteria for low risk disease and 153 had very low risk disease. The proportion of subjects at low risk found to have Gleason score upgrade or nonorgan confined cancer on final pathology was 21.8% and 23.1%, respectively. Corresponding values in those at very low risk were 13.1% and 8.5%, respectively. After adjusting for age, race, year of surgery, body mass index, and prostate specific antigen at diagnosis, the relative risk of Gleason score upgrade in men with low risk vs very low risk disease was 1.89 (95% CI 1.21-2.95). The relative risk of nonorgan confined cancer was 2.06 (95% CI 1.19-3.57).
CONCLUSIONS: Men with very low risk prostate cancer were at significantly lower risk for adverse findings at surgery compared to those with low risk disease. These data support the stratification of low risk cancer when selecting and counseling men who may be appropriate for active surveillance.
Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AS; BMI; GS; Gleason score; LR; NOCC; PSA; VLR; active surveillance; body mass index; disease progression; low risk; nonorgan confined cancer; prostate; prostate specific antigen; prostatic neoplasms; risk; treatment outcome; very LR

Mesh:

Year:  2013        PMID: 23643603      PMCID: PMC3978170          DOI: 10.1016/j.juro.2013.04.071

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  30 in total

Review 1.  Overdiagnosis in cancer.

Authors:  H Gilbert Welch; William C Black
Journal:  J Natl Cancer Inst       Date:  2010-04-22       Impact factor: 13.506

2.  NCCN clinical practice guidelines in oncology: prostate cancer.

Authors:  James Mohler; Robert R Bahnson; Barry Boston; J Erik Busby; Anthony D'Amico; James A Eastham; Charles A Enke; Daniel George; Eric Mark Horwitz; Robert P Huben; Philip Kantoff; Mark Kawachi; Michael Kuettel; Paul H Lange; Gary Macvicar; Elizabeth R Plimack; Julio M Pow-Sang; Mack Roach; Eric Rohren; Bruce J Roth; Dennis C Shrieve; Matthew R Smith; Sandy Srinivas; Przemyslaw Twardowski; Patrick C Walsh
Journal:  J Natl Compr Canc Netw       Date:  2010-02       Impact factor: 11.908

3.  Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.

Authors:  Jonas Hugosson; Sigrid Carlsson; Gunnar Aus; Svante Bergdahl; Ali Khatami; Pär Lodding; Carl-Gustaf Pihl; Johan Stranne; Erik Holmberg; Hans Lilja
Journal:  Lancet Oncol       Date:  2010-07-02       Impact factor: 41.316

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

5.  Outcomes of active surveillance for men with intermediate-risk prostate cancer.

Authors:  Matthew R Cooperberg; Janet E Cowan; Joan F Hilton; Adam C Reese; Harras B Zaid; Sima P Porten; Katsuto Shinohara; Maxwell V Meng; Kirsten L Greene; Peter R Carroll
Journal:  J Clin Oncol       Date:  2010-11-29       Impact factor: 44.544

Review 6.  Active surveillance for prostate cancer: a systematic review of the literature.

Authors:  Marc A Dall'Era; Peter C Albertsen; Christopher Bangma; Peter R Carroll; H Ballentine Carter; Matthew R Cooperberg; Stephen J Freedland; Laurence H Klotz; Christopher Parker; Mark S Soloway
Journal:  Eur Urol       Date:  2012-06-07       Impact factor: 20.096

7.  Expectant management of nonpalpable prostate cancer with curative intent: preliminary results.

Authors:  H Ballentine Carter; Patrick C Walsh; Patricia Landis; Jonathan I Epstein
Journal:  J Urol       Date:  2002-03       Impact factor: 7.450

8.  Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study.

Authors:  Roderick C N van den Bergh; Hanna Vasarainen; Henk G van der Poel; Jenneke J Vis-Maters; John B Rietbergen; Tom Pickles; Erik B Cornel; Riccardo Valdagni; Joris J Jaspars; John van der Hoeven; Frederic Staerman; Eric H G M Oomens; Antti Rannikko; Stijn Roemeling; Ewout W Steyerberg; Monique J Roobol; Fritz H Schröder; Chris H Bangma
Journal:  BJU Int       Date:  2009-10-08       Impact factor: 5.588

9.  Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

Authors:  Gerrit Draisma; Rob Boer; Suzie J Otto; Ingrid W van der Cruijsen; Ronald A M Damhuis; Fritz H Schröder; Harry J de Koning
Journal:  J Natl Cancer Inst       Date:  2003-06-18       Impact factor: 13.506

Review 10.  PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer.

Authors:  Jeffrey Tosoian; Stacy Loeb
Journal:  ScientificWorldJournal       Date:  2010-10-01
View more
  33 in total

1.  Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI.

Authors:  Mrishta Brizmohun Appayya; Harbir S Sidhu; Nikolaos Dikaios; Edward W Johnston; Lucy Am Simmons; Alex Freeman; Alexander Ps Kirkham; Hashim U Ahmed; Shonit Punwani
Journal:  Br J Radiol       Date:  2017-12-15       Impact factor: 3.039

2.  Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy.

Authors:  Yaw A Nyame; Adam B Murphy; Diana K Bowen; Gregory Jordan; Ken Batai; Michael Dixon; Courtney M P Hollowell; Stephanie Kielb; Joshua J Meeks; Peter H Gann; Virgilia Macias; Andre Kajdacsy-Balla; William J Catalona; Rick Kittles
Journal:  J Clin Oncol       Date:  2016-02-22       Impact factor: 44.544

Review 3.  Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools.

Authors:  Jeffrey J Tosoian; Stacy Loeb; Jonathan I Epstein; Baris Turkbey; Peter L Choyke; Edward M Schaeffer
Journal:  Am Soc Clin Oncol Educ Book       Date:  2016

4.  Multiparametric 3T MRI for the prediction of pathological downgrading after radical prostatectomy in patients with biopsy-proven Gleason score 3 + 4 prostate cancer.

Authors:  Tatsuo Gondo; Hedvig Hricak; Evis Sala; Junting Zheng; Chaya S Moskowitz; Melanie Bernstein; James A Eastham; Hebert Alberto Vargas
Journal:  Eur Radiol       Date:  2014-08-07       Impact factor: 5.315

5.  Identification of threshold prostate specific antigen levels to optimize the detection of clinically significant prostate cancer by magnetic resonance imaging/ultrasound fusion guided biopsy.

Authors:  Nabeel A Shakir; Arvin K George; M Minhaj Siddiqui; Jason T Rothwax; Soroush Rais-Bahrami; Lambros Stamatakis; Daniel Su; Chinonyerem Okoro; Dima Raskolnikov; Annerleim Walton-Diaz; Richard Simon; Baris Turkbey; Peter L Choyke; Maria J Merino; Bradford J Wood; Peter A Pinto
Journal:  J Urol       Date:  2014-08-09       Impact factor: 7.450

Review 6.  Active surveillance for prostate cancer.

Authors:  Javier Romero-Otero; Borja García-Gómez; José M Duarte-Ojeda; Alfredo Rodríguez-Antolín; Antoni Vilaseca; Sigrid V Carlsson; Karim A Touijer
Journal:  Int J Urol       Date:  2015-11-30       Impact factor: 3.369

7.  Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions.

Authors:  Anwar R Padhani; Jeffrey Weinreb; Andrew B Rosenkrantz; Geert Villeirs; Baris Turkbey; Jelle Barentsz
Journal:  Eur Urol       Date:  2018-06-13       Impact factor: 20.096

Review 8.  Active surveillance for prostate cancer: current evidence and contemporary state of practice.

Authors:  Jeffrey J Tosoian; H Ballentine Carter; Abbey Lepor; Stacy Loeb
Journal:  Nat Rev Urol       Date:  2016-03-08       Impact factor: 14.432

9.  Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer.

Authors:  Thomas P Frye; Arvin K George; Amichai Kilchevsky; Mahir Maruf; M Minhaj Siddiqui; Michael Kongnyuy; Akhil Muthigi; Hui Han; Howard L Parnes; Maria Merino; Peter L Choyke; Baris Turkbey; Brad Wood; Peter A Pinto
Journal:  J Urol       Date:  2016-09-06       Impact factor: 7.450

10.  Clinical role of pathological downgrading after radical prostatectomy in patients with biopsy confirmed Gleason score 3 + 4 prostate cancer.

Authors:  Tatsuo Gondo; Bing Ying Poon; Kazuhiro Matsumoto; Melanie Bernstein; Daniel D Sjoberg; James A Eastham
Journal:  BJU Int       Date:  2014-08-13       Impact factor: 5.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.